Promethazine HCl & Codeine Phosphate Oral Solution Recalled Due to Manufacturing Compliance Deviations
Akorn Inc. is recalling all lots of Promethazine HCl & Codeine Phosphate Oral Solution nationwide because the firm went out of business and cannot complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall where the firm's closure prevented completion of required stability studies. While no illnesses or injuries have been reported, the inability to verify product stability for a prescription medication represents a risk-of-harm situation under the rubric criteria for Score 3.
Plain-English summary
Akorn Inc. is recalling all lots of Promethazine HCl & Codeine Phosphate Oral Solution, 6.25mg/10mg per 5 mL (Rx only), distributed nationwide in the USA and Puerto Rico. The recall is due to Current Good Manufacturing Practice (CGMP) deviations.
The firm went out of business and could no longer continue stability studies for the product. All National Drug Code (NDC) numbers and all product lots are affected by this recall.
The recalled product
- Product
- Promethazine HCl & Codeine Phosphate Oral Solution, USP, 6.25mg/10mg per 5 mL, Rx Only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- HighProparacaine Ophthalmic Solution Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-01-25
- HighPromethazine With Codeine Oral Solution Recall Due to Microbial Contamination
FDA (Drugs) · 2021-09-29
- SevereAkorn Recalls Hydroxyzine Hydrochloride Oral Solution Due to Impurities
FDA (Drugs) · 2015-06-17
- ModerateDrug recall: Proparacaine eye solution due to manufacturing deviations
FDA (Drugs) · 2023-01-25
- ModerateAkorn Recalls Gabapentin Oral Solution Due to Impurity Specifications
FDA (Drugs) · 2021-03-24
- LowAkorn Recalls Prednisolone Sodium Phosphate Oral Solution Due to Discoloration
FDA (Drugs) · 2020-06-17